Catriona Yale insider trades: Akero Therapeutics (AKRO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Catriona reports to the SEC
Open-market buys and sales
40 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | AKRO | ↓ Sell | 659 | $43.02 | $28K | Direct | Sep 12, 2025 (1d) |
| Jul 16, 2025 | AKRO | ↓ Sell | 10,000 | $52.95 | $529K | Direct | Jul 18, 2025 (2d) |
| Jun 18, 2025 | AKRO | ↓ Sell | 1,633 | $54.84 | $90K | Direct | Jun 20, 2025 (2d) |
| Jun 16, 2025 | AKRO | ↓ Sell | 10,000 | $54.23 | $542K | Direct | Jun 20, 2025 (4d) |
| Jun 10, 2025 | AKRO | ↓ Sell | 2,803 | $54.00 | $151K | Direct | Jun 12, 2025 (2d) |
| May 15, 2025 | AKRO | ↓ Sell | 10,000 | $39.30 | $393K | Direct | May 19, 2025 (4d) |
| Apr 15, 2025 | AKRO | ↓ Sell | 9,073 | $37.91 | $344K | Direct | Apr 16, 2025 (1d) |
| Mar 17, 2025 | AKRO | ↓ Sell | 10,000 | $44.76 | $448K | Direct | Mar 18, 2025 (1d) |
| Mar 12, 2025 | AKRO | ↓ Sell | 614 | $44.88 | $28K | Direct | Mar 14, 2025 (2d) |
| Feb 18, 2025 | AKRO | ↓ Sell | 10,000 | $49.87 | $499K | Direct | Feb 21, 2025 (3d) |
| Jan 27, 2025 | AKRO | ↓ Sell | 53,590 | $56.25 | $3.0M | Direct | Jan 31, 2025 (4d) |
| Jan 27, 2025 | AKRO | ↓ Sell | 49,074 | $55.72 | $2.7M | Direct | Jan 31, 2025 (4d) |
| Dec 16, 2024 | AKRO | ↓ Sell | 9,074 | $29.11 | $264K | Direct | Dec 18, 2024 (2d) |
| Dec 10, 2024 | AKRO | ↓ Sell | 2,810 | $30.79 | $87K | Direct | Dec 12, 2024 (2d) |
| Nov 15, 2024 | AKRO | ↓ Sell | 9,061 | $27.73 | $251K | Direct | Nov 19, 2024 (4d) |
| Nov 6, 2024 | AKRO | ↓ Sell | 10,000 | $35.19 | $352K | Direct | Nov 8, 2024 (2d) |
| Nov 1, 2024 | AKRO | ↓ Sell | 20,000 | $32.60 | $652K | Direct | Nov 1, 2024 (0d) |
| Oct 15, 2024 | AKRO | ↓ Sell | 20,961 | $30.37 | $636K | Direct | Oct 16, 2024 (1d) |
| Sep 20, 2024 | AKRO | ↓ Sell | 5,500 | $27.65 | $152K | Direct | Sep 23, 2024 (3d) |
| Sep 18, 2024 | AKRO | ↓ Sell | 8,393 | $27.54 | $231K | Direct | Sep 18, 2024 (0d) |
| Sep 10, 2024 | AKRO | ↓ Sell | 637 | $26.18 | $17K | Direct | Sep 13, 2024 (3d) |
| Sep 3, 2024 | AKRO | ↓ Sell | 949 | $27.61 | $26K | Direct | Sep 5, 2024 (2d) |
| Aug 26, 2024 | AKRO | ↓ Sell | 14,051 | $27.52 | $387K | Direct | Aug 28, 2024 (2d) |
| Jun 11, 2024 | AKRO | ↓ Sell | 2,825 | $22.64 | $64K | Direct | Jun 13, 2024 (2d) |
| Mar 13, 2024 | AKRO | ↓ Sell | 723 | $28.33 | $20K | Direct | Mar 15, 2024 (2d) |
| Mar 4, 2024 | AKRO | ↓ Sell | 20,646 | $35.49 | $733K | Direct | Mar 6, 2024 (2d) |
| Dec 14, 2023 | AKRO | ↓ Sell | 597 | $20.76 | $12K | Direct | Dec 18, 2023 (4d) |
| Sep 21, 2023 | AKRO | ↓ Sell | 5,617 | $48.32 | $271K | Direct | Sep 25, 2023 (4d) |
| Aug 28, 2023 | AKRO | ↓ Sell | 5,745 | $49.99 | $287K | Direct | Aug 30, 2023 (2d) |
| Jun 23, 2023 | AKRO | ↓ Sell | 33,349 | $51.74 | $1.7M | Direct | Jun 23, 2023 (0d) |
| Jun 13, 2023 | AKRO | ↓ Sell | 591 | $55.16 | $33K | Direct | Jun 15, 2023 (2d) |
| Jan 13, 2023 | AKRO | ↓ Sell | 5,000 | $50.53 | $253K | Direct | Jan 18, 2023 (5d) |
| Dec 12, 2022 | AKRO | ↓ Sell | 5,000 | $43.23 | $216K | Direct | Dec 13, 2022 (1d) |
| Nov 10, 2022 | AKRO | ↓ Sell | 5,000 | $39.42 | $197K | Direct | Nov 14, 2022 (4d) |
| Oct 10, 2022 | AKRO | ↓ Sell | 5,000 | $37.99 | $190K | Direct | Oct 12, 2022 (2d) |
| Sep 13, 2022 | AKRO | ↓ Sell | 40,000 | $27.48 | $1.1M | Direct | Sep 15, 2022 (2d) |
| Oct 15, 2021 | AKRO | ↓ Sell | 12,500 | $21.59 | $270K | Direct | Oct 18, 2021 (3d) |
| Sep 15, 2021 | AKRO | ↓ Sell | 12,500 | $24.69 | $309K | Direct | Sep 17, 2021 (2d) |
| Aug 16, 2021 | AKRO | ↓ Sell | 10,000 | $18.79 | $188K | Direct | Aug 17, 2021 (1d) |
| Jul 15, 2021 | AKRO | ↓ Sell | 10,000 | $20.90 | $209K | Direct | Jul 19, 2021 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Catriona Yale's insider trades
Catriona Yale is Chief Development Officer at Akero Therapeutics (AKRO). Since Jul 15, 2021, Catriona has reported no open-market purchases and 40 sales worth $17.9M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (21 filings), grants and awards (11 filings), shares returned to the company (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKRO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.